Person:
YURTSEVER, İSMAİL

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
İSMAİL
Last Name
YURTSEVER
Name
Email Address
Birth Date

Filters

2018 - 201922020 - 20228
Reset filters

Settings

Author: TÜRK, HACI MEHMET ×

Search Results

Now showing 1 - 10 of 10
  • No Thumbnail Available
    PublicationMetadata only
    Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study.
    (2020-02-25T00:00:00Z) Türk, HM; Gültekin, MEHMET ALİ; Uysal, Ö; Beşiroğlu, M; Yilmaz, TF; Yurtsever, I; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; TOPRAK, HÜSEYİN; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; SHARIFOV, RASUL; UYSAL, ÖMER
    Purpose: We aimed to investigate whether there are any differences in apparent diffusion coefficient (ADC) values obtained from colorectal liver metastases (CRLM) according to Kirsten rat sarcoma (KRAS) gene mutation status.
  • Thumbnail Image
    PublicationOpen Access
    Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer.
    (2021-03-04T00:00:00Z) Bilgin, Sabriye Sennur; Gultekin, Mehmet Ali; Yurtsever, Ismail; Yilmaz, Temel Fatih; Cesme, Dilek Hacer; Bilgin, Melike; Topcu, Atakan; Besiroglu, Mehmet; Turk, Haci Mehmet; Alkan, ALPAY; Bilgin, Mehmet; GÜLTEKİN, MEHMET ALİ; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; ÇEŞME, DİLEK HACER; TÜRK, HACI MEHMET; ALKAN, ALPAY; BİLGİN, MEHMET
    Purpose: Histopathological differentiation of primary lung cancer is clinically important. We aimed to investigate whether diffusion tensor imaging (DTI) parameters of metastatic brain lesions could predict the histopathological types of the primary lung cancer. Methods: In total, 53 patients with 98 solid metastatic brain lesions of lung cancer were included. Lung tumors were subgrouped as non-small cell carcinoma (NSCLC) (n = 34) and small cell carcinoma (SCLC) (n = 19). Apparent diffusion coefficient (ADC) and Fractional anisotropy (FA) values were calculated from solid enhanced part of the brain metastases. The association between FA and ADC values and histopathological subtype of the primary tumor was investigated. Results: The mean ADC and FA values obtained from the solid part of the brain metastases of SCLC were significantly lower than the NSCLC metastases (P < 0.001 and P = 0.003, respectively). ROC curve analysis showed diagnostic performance for mean ADC values (AUC=0.889, P = < 0.001) and FA values (AUC = 0.677, P = 0.002). Cut-off value of > 0.909 × 10-3 mm2/s for mean ADC (Sensitivity = 80.3, Specificity = 83.8, PPV = 89.1, NPV = 72.1) and > 0.139 for FA values (Sensitivity = 80.3, Specificity = 54.1, PPV = 74.2, NPV= 62.5) revealed in differentiating NSCLC from NSCLC. Conclusion: DTI parameters of brain metastasis can discriminate SCLC and NSCLC. ADC and FA values of metastatic brain lesions due to the lung cancer may be an important tool to differentiate histopathological subgroups. DTI may guide clinicians for the management of intracranial metastatic lesions of lung cancer.
  • Thumbnail Image
    PublicationOpen Access
    The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.
    (2022-05-14T00:00:00Z) Topcu, Atakan; Ozturk, Akin; Yurtsever, İSMAİL; Besiroglu, Mehmet; Yasin, Ayse Irem; Turk, Haci Mehmet; Seker, Mesut; YURTSEVER, İSMAİL; TÜRK, HACI MEHMET
    Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.
  • No Thumbnail Available
    PublicationMetadata only
    Meme kanseri beyin metastazlarının moleküler subgruplarının difüzyon tensor görüntüleme ile değerlendirilmesi
    (2019-04-27T00:00:00Z) Yurtsever, İsmail; Gültekin, Mehmet Ali; Yılmaz, Temel Fatih; Türk, Hacı Mehmet; Alkan, Alpay; YURTSEVER, İSMAİL; GÜLTEKİN, MEHMET ALİ; YILMAZ, TEMEL FATİH; TÜRK, HACI MEHMET; ALKAN, ALPAY
  • No Thumbnail Available
    PublicationMetadata only
    Akciğer kanserli olgularda intrakranial metastazlarının primer hücre tipinin belirlenmesinde DTG’nin etkinliği
    (2018-11-10T00:00:00Z) Bilgin, Mehmet; Yurtsever, İsmail; Türk, Hacı Mehmet; Alkan, Alpay; BİLGİN, MEHMET; YURTSEVER, İSMAİL; TÜRK, HACI MEHMET; ALKAN, ALPAY
  • No Thumbnail Available
    PublicationMetadata only
    The Utility and Efficiency of Diffusion Tensor Imaging Values to Determine Epidermal Growth Factor Receptor Gene Mutation Status in Brain Metastasis from Lung Adenocarcinoma; A Preliminary Study
    (2021-02-01T00:00:00Z) Gültekin, Mehmet Ali; Alkan, Alpay; Yılmaz, Temel Fatih; Yurtsever, İsmail; Atasoy, Bahar; Aliyev, Altay; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; ALKAN, ALPAY
  • No Thumbnail Available
    PublicationMetadata only
    A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer
    (2021-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, Mesut; TÜRK, HACI MEHMET; TOPÇU, ATAKAN; YASİN, AYŞE İREM; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, MESUT; TÜRK, HACI MEHMET
    Introduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.
  • No Thumbnail Available
    PublicationMetadata only
    Relationship with programmed cell death ligand 1 (PD-L1) and DTI features in brain metastases of non-small cell lung cancer; Preliminary study.
    (2021-02-17T00:00:00Z) Yurtsever, İsmail; Yilmaz, Temel Fatih; Turk, Hacı Mehmet; Gultekin, Mehmet Ali; Besiroglu, Mehmet; Cesme, DİLEK HACER; Shbair, Abdallah T M; Alkan, ALPAY; YILMAZ, TEMEL FATİH; YURTSEVER, İSMAİL; TÜRK, HACI MEHMET; GÜLTEKİN, MEHMET ALİ; ÇEŞME, DİLEK HACER; ALKAN, ALPAY
  • No Thumbnail Available
    PublicationMetadata only
    Diffusion Tensor Imaging of Brain Metastases in Patients with Breast Cancer According to Molecular Subtypes.
    (2020-06-21T00:00:00Z) Turk, HM; Sari, L; Yurtsever, I; Yabaci, A; Peker, AA; Alkan, ALPAY; YURTSEVER, İSMAİL; GÜLTEKİN, MEHMET ALİ; TOPRAK, HÜSEYİN; TÜRK, HACI MEHMET; YABACI TAK, AYŞEGÜL; ALKAN, ALPAY
  • No Thumbnail Available
    PublicationMetadata only
    Apparent Diffusion Coefficient Values for Neuroendocrine Liver Metastases.
    (2020-11-07T00:00:00Z) Gultekin, MA; Cesme, DH; Yurtsever, I; Turk, HM; Seker, M; Besiroglu, M; Alkan, ALPAY; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; YURTSEVER, İSMAİL; ÇEŞME, DİLEK HACER; ALKAN, ALPAY